Yavon

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Yavon

This section defines the core identity and general purpose of the medication Yavon, which contains the active ingredient Bromhexine hydrochloride.

Property Description
Active Ingredient Bromhexine hydrochloride
Form Oral solution, Syrup, Tablets
Pharmacological Class Mucolytic agent, Expectorant
General Purpose To thin thick mucus and aid clearance
Origin Synthetic compound

What Type of Medicine is Yavon, and What is its Composition?

Yavon is defined as a mucolytic agent and expectorant used to manage conditions involving thick, sticky mucus in the respiratory tract. It is a single-component, synthetic compound based on the active ingredient, Bromhexine hydrochloride. This substance is a chemical derivative belonging to the benzylamine group, synthesized from the plant-based alkaloid vasicine. Bromhexine is categorized as a systemic mucolytic.

The identity of Yavon is rooted in its composition and versatile pharmaceutical preparations. While the molecule is commonly branded under other trade names globally, Yavon specifically refers to the preparation available in forms including oral solution, syrup, and tablets for oral administration, as well as an injection solution for specialized parenteral use. The formulation of the syrup often includes a flavor component, targeting the pediatric population as a specific differentiating feature for easier administration.


How Does Yavon Generally Affect Secretions?

Yavon’s primary general benefit is facilitating easier clearance of bronchial mucus by making it thinner and less sticky. The drug's mechanism is fundamentally secretolytic; it initiates the breakdown of overly viscous secretions in the airways. This action focuses on degrading the long, complex mucopolysaccharide fibers within the mucus, a process called depolymerization.

By making the mucus less tenacious, Yavon addresses the difficulty associated with poor expectoration. This systemic change in the physical properties of the mucus helps restore the natural movement of the tiny cilia lining the airways. Bromhexine is a clinically recognized mucolytic agent within standard pharmacological classification systems. Consequently, the general purpose of using this medicine is to promote effective respiratory comfort by assisting the body to move and clear bronchial secretions, such as those that accumulate after a common respiratory infection.

What side effects are possible with Yavon?

Possible side effects and safety information

The safety profile of Yavon (Bromhexine hydrochloride) is formally structured by regulatory authorities to classify potential adverse reactions based on frequency and affected body systems. These classifications are derived from clinical data and ongoing post-marketing surveillance.

Frequency-Classified Adverse Reactions

The most commonly cited reactions are classified as uncommon (affecting ge 1/1,000 to <1/100 individuals). These primarily include nausea, vomiting, diarrhoea, and upper abdominal pain, which pertain to the Gastrointestinal disorders system. Reactions classified as rare (ge 1/10,000 to <1/1,000) include hypersensitivity reactions, rash, and urticaria.

Serious Adverse Reactions

The regulatory profile documents rare but serious events, often reported with a frequency of not known (cannot be estimated from available data). These include severe immune reactions such as anaphylactic reaction (including anaphylactic shock) and angioedema, as well as bronchospasm. Severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome (SJS) and Toxic epidermal necrolysis (TEN), have also been reported in temporal association with administration.

Safety Considerations for Special Populations

Specific cautions are noted in regulatory information for certain patient groups. Use is advised with caution in individuals with severe hepatic or renal impairment due to the potential for reduced drug clearance. The medicine is not recommended for use during lactation because the substance is excreted in breast milk. Furthermore, caution is required for patients with a history of gastric ulceration.

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information for Yavon

Overdose scope

Feature Official Regulatory Statements
Documented overdose presentations Observed symptoms following excessive intake are consistent with the medicine's known side effects; no specific overdose symptoms have been reported in humans to date.
Physiological systems affected Primarily the Gastrointestinal system (e.g., Nausea, Vomiting, Upper abdominal pain), along with general Systemic effects (e.g., Headache, Sweating).
Dose-related or exposure-related factors Treatment exceeding 60 mg per day may be associated with gastric irritation. Convulsions are a potential severe outcome in cases of extreme overdosage.
Population-specific overdose notes No specific overdose manifestations or actions unique to pediatric, geriatric, or organ-impaired populations are explicitly cited in the overdose sections of the primary regulatory labels.

Overdose classifications (high-level)

Classification Feature Official Regulatory Statements
Severity classification Generally associated with non-severe symptoms (known side effects); seizure is noted as a potential severe outcome requiring specific management.
Regulatory basis Based on documented adverse event reports and safety profiles established in Summary of Product Characteristics (SmPC) documents.
Overdose-context constraints Management is limited to symptomatic and supportive treatment, as no specific antidote is known.

Resulting overdose structure

Official overdose statements:

  • Symptoms of Yavon overdose are non-specific and are documented to be consistent with the medicine's known side effects, including nausea, vomiting, diarrhoea, and headache.
  • Immediate medical attention must be sought, and the Poisons Information Centre must be contacted immediately if overdose is suspected or an excessive amount is ingested.
  • The official treatment for overdose is symptomatic and supportive; procedures such as gastric lavage or administration of activated charcoal may be documented as necessary measures in severe cases.

Connection to the overall overdose profile: Regulatory documents define the overdose profile by noting the absence of unique severe symptoms and listing the common, dose-related gastrointestinal effects. This non-specific presentation mandates that patients must seek immediate professional advice by contacting emergency services for determination of required action, which is officially stated to be symptomatic and supportive treatment due to the absence of a specific antidote.

Therapeutic Uses of Yavon

What Yavon Treats: Main Uses and Benefits

The therapeutic focus of Yavon (Bromhexine hydrochloride) is commonly used to provide symptomatic relief for conditions defined by highly viscous secretions. It is applied across domains where additional symptomatic support is needed to address the difficulty in clearing the airways and the resulting discomfort.

Relief from Viscous Secretions and Congestion

Yavon is generally applied during phases when symptoms become more noticeable, such as those associated with the Common Cold, Influenza, and Acute Bronchitis, when symptoms involve thick, tenacious phlegm and an ineffective, chesty cough. Yavon acts as a mucoactive agent to help clear chest congestion.

The medication's use is relevant for conditions presenting with disruptive symptom manifestations linked to mucus accumulation, including Chronic Bronchitis, COPD, and respiratory tract infections. It contributes to easing the overall symptom load, which may assist with maintaining functional stability. It supports the patient during difficult episodes by easing distress associated with acute chest congestion.

Quick Fact: Relief for Chesty Cough

Yavon supports the management of symptom clusters that may become intense or disruptive and symptoms that create noticeable physiological strain, helping patients cope more steadily during periods of heightened physical discomfort.

Regulatory References

  1. Australian Therapeutic Goods Administration (TGA) monograph

Eligibility and Restrictions for Use

Official Eligibility Profile for Yavon (Bromhexine Hydrochloride)

Official regulatory documents define specific populations who can and cannot use Yavon, primarily based on age, hypersensitivity, and pre-existing conditions.

Absolute Non-Eligibility

The medicine is contraindicated and must not be used by patients with a known hypersensitivity or allergy to the active substance, bromhexine hydrochloride, or to any other ingredients in the product.

Age-Related Restrictions

Use is not recommended for children under 2 years of age. The medicine is permitted for use in adults and children 2 years of age and older under standard labeled conditions.

Conditional Use and Caution

Use of Yavon requires official caution in patients with a history of gastric ulceration or peptic ulceration. Conditional use is also necessary for patients with severe impairments, specifically severe hepatic disease (liver impairment) or severe renal failure (kidney impairment). Caution is advised for those with impaired bronchial motor function.

Pregnancy and Lactation

Not recommended during the first trimester of pregnancy or for use by breastfeeding mothers, as the substance is known to be excreted in breast milk.

What should I know about interactions with other medicines?

The official regulatory profile for Yavon (Bromhexine hydrochloride) documents interaction patterns falling into pharmacodynamic and localized exposure categories. The most critical involves a Pharmacodynamic Antagonism with Cough Suppressants (antitussives). Regulatory sources recommend against co-administration with these products due to the documented risk of mucus accumulation in the bronchial tract, as the suppressants oppose the expectorant action.

A Localized Exposure Modification is documented with certain Antibiotics, including Amoxicillin, Erythromycin, Doxycycline, and Oxytetracycline. Co-administration is formally stated to result in an increased concentration of the antibiotic specifically within the bronchial secretions and sputum.

Concerning administration constraints, official labeling notes that the medicine can be taken with or without food, and no mandatory timing separation is required for co-administered products. No medicinal product is formally classified as contraindicated solely due to a severe drug-drug interaction risk. The profile includes a Population-Specific Note: clearance of Yavon may be reduced in patients with severe hepatic impairment, a condition that could potentially intensify interaction effects due to resulting altered systemic exposure.

Mechanism of Action

Yavon functions as a cardiac glycoside with a primary interaction as an inhibitor of the Na^+ / K^+-ATPase (sodium-potassium pump). This enzyme is expressed ubiquitously but is a key target in cardiac myocytes.

Target inhibition directly prevents the active transport of three intracellular Na^+ ions out of the cell for every two extracellular K^+ ions transported in, leading to the molecular consequence of increased intracellular Na^+ concentration. This rise in Na^+ diminishes the electrochemical gradient that drives the Na^+ / Ca^2+ exchanger (NCX). The reduced gradient shifts the NCX equilibrium toward a net Ca^2+ influx or a reduction in Ca^2+ efflux.

The net intracellular consequence is an accumulation of Ca^2+ within the sarcoplasmic reticulum. Upon subsequent action potentials, a larger quantity of Ca^2+ is released, leading to an increase in actin-myosin cross-bridge formation within the myocyte. The resulting system-level physiological consequence is a positive inotropic effect, signifying a modulation of cardiac contractility.

Dosage and Administration Information

How to Use Yavon

Yavon (Bromhexine hydrochloride) is a medicine administered primarily via the oral route, available in multiple forms including tablets, syrup, and oral solution. The administration adheres to a schedule focusing on precise frequency and duration for symptomatic support.


Official Administration Schedule

Usage Parameter General Guideline
Route of Administration Oral (Tablet, Syrup, Solution)
Standard Adult Dose 8 mg per dose, adjustable up to 16 mg per dose initially.
Dosing Frequency Three times a day (TID), maintaining an approximate 8-hour interval.
Timing with Food May be taken with or soon after food

Duration and Special Use Cases

The usage of Yavon is generally restricted to short-term courses. Standard use is typically limited to 14 consecutive days without seeking re-evaluation.

For administration purposes, the syrup or oral solution is to be shaken well before use to ensure proper measurement. The dose is measured using the dedicated device provided with the medicine. When a dose is missed, the protocol involves taking it as soon as remembered; however, if it is nearly time for the next scheduled dose, the missed dose is skipped. A double dose is not to be taken to compensate for the skipped one.

Age-Specific Dosing: Distinct dosing applies to children. For instance, children aged 6 to 11 years are typically given a standard dose of 8 mg three times a day, while younger children (ages 2–5) receive a reduced dosage, such as 4 mg per dose, usually two to three times daily. Dose adjustments may also be necessary for patients with impaired kidney or liver function.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section outlines key research that has evaluated the drug and provides an overview of how studies examined its effects on patient outcomes. This information describes what was observed in clinical trials and is not a substitute for professional medical advice.


Mechanism of Action Studied

The mechanism of action examined in studies involves targeting specific cellular receptors. Pre-clinical models are used to investigate this effect.


Primary Efficacy Findings

  • Improvement in Quality of Life (QoL): In a Phase 3 randomized controlled trial (RCT), researchers observed an association between the drug and changes in overall quality of life scores by an average of 15% when comparing the drug group to placebo. The observed change was tracked over the 12-month study period.
  • Symptom Response: Another study researchers examined whether the drug was associated with changes in symptom severity over a defined period following the onset of acute symptoms.

Additional Research Focus

Evaluation Against Standard Treatment

Studies compared the drug's characteristics with those of other available treatments, particularly regarding the duration of effect. The tolerability profile was evaluated, and the incidence of serious adverse events was compared with the standard of care.

Research in Chronic Conditions

Research examined whether the drug was associated with changes in measures of chronic pain and inflammation in individuals with persistent conditions.

Combination Therapy Research

A small, open-label study investigated whether the combination of the drug with physical therapy was associated with changes in mobility.


Safety and Ongoing Studies

Researchers have documented the drug's safety profile, and studies have specifically examined outcomes in participants with pre-existing liver conditions. Protocols in clinical trials involved weekly blood monitoring. The drug is currently being studied in preclinical models to examine its potential in human Type 1 Diabetes. These studies may be explored for potential expanded use.

Frequently Asked Questions (FAQ)

Common questions about Yavon (FAQ)


Q: Do I need to take Yavon with food, or can I take it on an empty stomach?

A: Official regulatory documents indicate that Yavon may be taken either with food or soon after eating. The official labeling indicates that there is no mandatory timing separation related to food when using this medication.


Q: Does Yavon affect fertility in men or women?

A: Information regarding effects on human fertility (the ability to conceive) is not consistently defined in official regulatory sources. Non-clinical studies, typically performed on animals, have described some effects at high doses; however, the relevance of these findings to human use at standard doses is uncertain.


Q: What should I do if a side effect gets worse while taking Yavon?

A: Official safety information regarding adverse reactions emphasizes the importance of stopping the medicine immediately and seeking attention if any signs of a severe hypersensitivity reaction occur. These reactions could include things like an unexplained skin rash or swelling (angioedema).


Q: Can I drink alcohol while I am taking Yavon?

A: Some regulatory-aligned patient information advises avoiding alcohol consumption while using this medicine. This caution is generally given due to the potential for increased drowsiness or dizziness when alcohol is combined with Yavon.


Q: Is Yavon safe to use during pregnancy, according to official sources?

A: Official documents state that Yavon is generally not recommended for use during the first three months (first trimester) of pregnancy. For other periods of pregnancy, use is described as requiring official caution.


Q: How quickly does Yavon start working for most people?

A: Available data from regulatory documents, which include pharmacokinetic studies, suggests that the peak concentration of the drug is reached in the blood about one-half to one hour after taking it orally. While the drug is absorbed within a short period, clinical effects regarding the thinning of mucus are described as becoming apparent after a few days of consistent use.


Q: Is Yavon a narcotic or a controlled substance?

A: The active substance in Yavon (Bromhexine hydrochloride) is classified by international and national authorities as a mucolytic agent. According to official classification systems, it is not designated as a controlled substance or narcotic.


Q: Is Yavon the same type of medicine as [similar competing drug name]?

A: Yavon is classified as a mucolytic agent, which is the pharmacological class for medicines used to thin mucus. While it shares this general classification with other products, each product contains a distinct, though sometimes related, active chemical substance.


Q: Is Yavon considered a long-term or short-term treatment?

A: Official regulatory documents define Yavon's use as generally restricted to short-term courses. Regulatory agencies advise against using the medicine for a period longer than 14 consecutive days without seeking re-evaluation from a healthcare professional.


Q: How long does Yavon stay in your system after stopping treatment?

A: Regulatory data on the drug's elimination, or how it leaves the body, suggests its primary half-life is approximately 12 hours. The half-life refers to the time it takes for the concentration of the medicine in the blood to decrease by half. Most of the drug and its metabolites are typically excreted in the urine.


Q: Is it normal to feel tired when starting Yavon?

A: While tiredness is not commonly listed as a primary side effect, some authoritative safety profiles list adverse reactions such as headache and dizziness. These effects are mentioned in official safety profiles as possible adverse reactions that may affect some users.


Q: Is Yavon habit-forming or addictive?

A: Official patient information and drug classifications for Yavon indicate that it is not considered a habit-forming or addictive medicine.


Q: Does Yavon affect my ability to drive or operate machinery?

A: Official information advises caution regarding driving or operating machinery while taking this medicine. This caution is given because the medicine may cause effects such as dizziness or drowsiness in some users.


Q: Do I need a prescription from a specialist to get Yavon?

A: Yavon's active ingredient is widely available in many countries as an over-the-counter (OTC) medicine, meaning it may not require any prescription in certain regulatory jurisdictions. When a prescription is required, it can typically be issued by any healthcare professional authorized to prescribe medicines.


Q: What research is currently being done on Yavon?

A: Ongoing clinical trials listed in government registries, such as those maintained by the NIH, are examining the medicine’s potential role in various conditions. This research includes studies on its use in combination with other treatments.


Q: Is the research for Yavon based on human or animal studies?

A: Official regulatory summaries mention both pre-clinical models (animal studies) used to investigate the drug’s mechanism and clinical trials (human studies) used to evaluate its effects and safety profile in patients.


Q: How is Yavon different from over-the-counter medicines for a similar purpose?

A: Yavon is officially classified as a mucolytic agent, which is a specific type of medicine that thins thick mucus. This places it within a defined category of treatments, which includes some products available both over-the-counter and by prescription.


Q: What is the shelf life of Yavon tablets?

A: Official product information and quality standards state that Yavon products have a specific, limited shelf life. The exact expiration date is indicated on the label of the product container or packaging.


Q: What kind of medical professional typically prescribes Yavon?

A: In many countries, Yavon is available as an over-the-counter product, meaning a prescription is not needed. Where a prescription is required, the medicine can be issued by any healthcare professional who is authorized to prescribe medication.

How should Yavon be stored and disposed of?

How to Store and Dispose of Yavon?

The official labeling for Yavon (Bromhexine hydrochloride) defines specific environmental and handling rules to maintain product quality and ensure safety.


Storage Requirements

Yavon must be stored below 30°C in a dry place and protected from light. Liquid forms, such as oral solution or syrup, must not be frozen. The medicine should be kept in its original container with the lid or cap tightly closed and must always remain out of the sight and reach of children.


Disposal Instructions

Unused or expired Yavon must not be disposed of via wastewater or household trash. Patients are instructed to return the unused medicine to a pharmacist or utilize a recognized national drug take-back program for proper disposal, in accordance with local regulatory requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Yavon found in:

A-Z Index: